CTXR News and Press, Citius Pharmaceuticals Inc.

2024-04-26 08:14:28 ET More on Citius Pharmaceuticals Citius resubmits marketing application for lymphoma therapy Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Read the full article on Seeking Alpha For further details see: Citius Pharmace...

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma PR Newswire National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA , to ...

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference PR Newswire CRANFORD, N.J. , April 4, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedic...

2024-03-18 09:26:42 ET More on Citius Pharmaceuticals Citius resubmits marketing application for lymphoma therapy Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citiu...

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma PR Newswire FDA assigns Prescription Drug User Fee Act (PDUFA) target action date ...

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program PR Newswire Net operating losses converted into non-dilutive capital CRANFORD, N.J. , March 7, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or...

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration PR Newswire CRANFORD, N.J. , Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a lat...

2024-02-23 16:38:15 ET More on Citius Pharmaceuticals Citius resubmits marketing application for lymphoma therapy Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citiu...

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences PR Newswire CRANFORD, N.J. , Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company de...

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update PR Newswire Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial C...